biotech

Lipid-Based Oral Form of Amphotericin B, Treats Fungal Infections with Fewer Side Effects

Filed in archive Diagnostics, Methodologies and Instrumentation , Drugs, Vaccines and Therapeutics on March 9, 2007

Lipid-Based Oral Form of Amphotericin B, Treats Fungal Infections with Fewer Side Effects
Blood-borne fungal infections that can be lethal for HIV/AIDS, cancer, and organ transplant patients can now be treated with a new drug delivery method.

Developed by researchers at the University of British Columbia in Vancouver (led by Pharmaceutical Sciences Prof. Kishor M. Wasan), a liquid preparation that incorporates drug molecules in fat (lipid-based formulation) so that Amphotericin B (a potent anti-fungal agent) can be taken orally with minimal side effects.

Being used for the past 50 years, Amphotericin B is currently administered intravenously but with toxic side effects: severe kidney toxicity and serious tissue damage at the intravenous injection site.

[Amphotericin B is also used to treat Leishmaniasis, a parasitic disease that affects an estimated two million people worldwide according to the Centers for Disease Control and Prevention.]

Wasan and his research team have discovered that the oral preparation triggers a different molecular interaction than intravenous delivery. The lipid-based system attacks fungal cells only while inhibiting the drug's interaction with kidney cells -- boosting effectiveness and dramatically reducing toxicity.


The oral form of Amphotericin B is cheaper and easier to administer, allowing more patients to have access to the medicine. This new delivery method of Amphotericin B has already been tested in animal models and is planned to be used in humans later this year.

The research findings have been recently presented at a meeting sponsored by the American Association of Pharmaceutical Scientists in Washington, D.C and will be published in July 2007 in Drug Development and Industrial Pharmacy.

Read the full report.

[Photo Credit: www.drugs.com]



Permalink: Lipid-Based Oral Form of Amphotericin B, Treats Fungal Infections with Fewer Side Effects

Tags: fungal  infections  Amphotericin  B  biotech  fungal+infections  lipid+based  side+effects 

Vote for Lipid-Based Oral Form of Amphotericin B, Treats Fungal Infections with Fewer Side Effects:

  • Currently 9.25/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.25 out of 4 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells